Therapy Areas: Respiratory
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
15 July 2026 - Chinese pharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HK:6990) announced on Tuesday that a Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-su...
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical C...
Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis
8 July 2026 - Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Tuesday the initiation of the Phase III clinical trial for Rentosertib, its potentially first-in-class ora...
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
2 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Thursday reported positive Phase III results from the Krascendo 1 trial evaluating investig...
Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC
2 July 2026 - Chinese biopharmaceutical company Abbisko Therapeutics Co Ltd (HKEX:02256) announced on Wednesday that it has entered into a strategic collaboration agreement with biopharmaceutical comp...
Co-Diagnostics advances toward FDA filing after completing clinical validation for respiratory point-of-care test
1 July 2026 - Molecular diagnostics company Co-Diagnostics Inc (Nasdaq: CODX) disclosed on Monday that it has completed clinical and analytical performance studies supporting its planned FDA submissio...